Payment overview · 2025
General Payments
$1,007.04
15 reported records · 7 companies
Healthcare provider profile · identity verified
Scott Middleton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LA HABRA, CA · NPI 1497742621
Verified facts
What the public records show
CMS Open Payments records show Scott Middleton, M.D. received $1,007.04 in general payments during 2025 across 15 reported records.
Becton, Dickinson and Company accounted for 69.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $700.00 | 69.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $67.81 | 6.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $66.50 | 6.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.10 | 6.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.10 | 4.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.49 | 3.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.04 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Honoraria | $700.00 | 1 |
| Food and Beverage | $307.04 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.81 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $67.81 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.10 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $64.10 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.10 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.90 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 132 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 75 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 127 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 44 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
132 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
117 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 44 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 929 | 297 |
| Levothyroxine Sodium | Levothyroxine Sodium | 776 | 213 |
| Tamsulosin Hcl | Tamsulosin Hcl | 411 | 120 |
| Omeprazole | Omeprazole | 372 | 118 |
| Amlodipine Besylate | Amlodipine Besylate | 371 | 127 |
| Metformin Hcl | Metformin Hcl | 338 | 117 |
| Simvastatin | Simvastatin | 335 | 95 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 84 |
| Alprazolam | Alprazolam | 249 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 74 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 240 | 95 |
| Meloxicam | Meloxicam | 240 | 70 |
| Furosemide | Furosemide | 224 | 76 |
| Lisinopril | Lisinopril | 214 | 81 |
| Fenofibrate | Fenofibrate | 210 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 209 | 49 |
| Temazepam | Temazepam | 202 | 41 |
| Irbesartan | Irbesartan | 190 | 61 |
| Glimepiride | Glimepiride | 183 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 182 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 59 |
| Finasteride | Finasteride | 178 | 51 |
| Lovastatin | Lovastatin | 174 | 54 |
| Eliquis | Apixaban | 173 | 44 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 162 | 49 |
| Potassium Chloride | Potassium Chloride | 162 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 53 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 156 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 32 |
| Farxiga | Dapagliflozin Propanediol | 150 | 40 |
| Gabapentin | Gabapentin | 149 | 60 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 71 |
| Tramadol Hcl | Tramadol Hcl | 139 | 45 |
| Jardiance | Empagliflozin | 132 | 44 |
| Ozempic | Semaglutide | 127 | 29 |
| Allopurinol | Allopurinol | 120 | 34 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 119 | 40 |
| Trulicity | Dulaglutide | 117 | 19 |
| Losartan Potassium | Losartan Potassium | 114 | 40 |
| Prednisone | Prednisone | 104 | 77 |
| Lorazepam | Lorazepam | 103 | 32 |
| Carvedilol | Carvedilol | 92 | 26 |
| Montelukast Sodium | Montelukast Sodium | 91 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 91 | 33 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 91 | 22 |
| Sildenafil Citrate | Sildenafil Citrate | 87 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 85 | 55 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 21 |
| Ibuprofen | Ibuprofen | 81 | 38 |
| Synthroid | Levothyroxine Sodium | 80 | 26 |
| Bupropion Xl | Bupropion Hcl | 78 | 22 |
| Azithromycin | Azithromycin | 77 | 64 |
| Celecoxib | Celecoxib | 77 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 32 |
| Myrbetriq | Mirabegron | 76 | 24 |
| Mounjaro | Tirzepatide | 75 | 16 |
| Ezetimibe | Ezetimibe | 73 | 23 |
| Testosterone | Testosterone | 73 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 72 | 26 |
| Atenolol | Atenolol | 70 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 69 | 23 |
| Klor-Con 10 | Potassium Chloride | 69 | 25 |
| Azelastine Hcl | Azelastine Hcl | 68 | 40 |
| Eszopiclone | Eszopiclone | 65 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 64 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 64 | 21 |
| Trazodone Hcl | Trazodone Hcl | 64 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 59 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | 23 |
| Donepezil Hcl | Donepezil Hcl | 57 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Famotidine | Famotidine | 56 | 19 |
| Sertraline Hcl | Sertraline Hcl | 55 | 18 |
| Alendronate Sodium | Alendronate Sodium | 54 | 18 |
| Baclofen | Baclofen | 54 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 52 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 53 | 15 |
| Warfarin Sodium | Warfarin Sodium | 53 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 17 |
| Lansoprazole | Lansoprazole | 50 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 48 | 32 |
| Valsartan | Valsartan | 48 | 14 |
| Estradiol | Estradiol | 47 | 20 |
| Ondansetron Odt | Ondansetron | 45 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 44 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 14 |
| Xarelto | Rivaroxaban | 43 | 12 |
| Terbinafine Hcl | Terbinafine Hcl | 42 | 30 |
| Testosterone Cypionate | Testosterone Cypionate | 42 | 11 |
| Benazepril Hcl | Benazepril Hcl | 40 | 14 |
| Ketoconazole | Ketoconazole | 39 | 19 |
| Modafinil | Modafinil | 39 | suppressed |
| Primidone | Primidone | 39 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 37 | 15 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 36 | 11 |
| Rizatriptan | Rizatriptan Benzoate | 36 | suppressed |
| Spironolactone | Spironolactone | 36 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 12 |
| Naproxen | Naproxen | 35 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Folic Acid | Folic Acid | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 11 |
| Torsemide | Torsemide | 32 | 13 |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Clonazepam | Clonazepam | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 30 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Metolazone | Metolazone | 25 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | 14 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | 11 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Cimetidine | Cimetidine | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 13 |
| Niacin Er | Niacin | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Prolia | Denosumab | 13 | suppressed |
| Valium | Diazepam | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bystolic | Nebivolol Hcl | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methyltestosterone | Methyltestosterone | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,007.04 · 15 records | Becton, Dickinson and Company | AREXVY, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error